Past events

The London Biotech Show is Europe’s flagship biotechnology event, connecting global leaders across biotech to accelerate innovation, partnerships, and investment shaping the future of healthcare and life sciences.

The World Orphan Drug Congress USA brings together the leading pharmaceutical and biotechnology companies, government and regulators, patient advocates, payers, investors, and solution providers – all who all depend on our event to convene and brainstorm ways to advance.

With over 700 participants attending in 2024, the Conference represents an unrivalled opportunity to network and exchange invaluable insights within the rare disease community. Through collaborative efforts, these discussions culminate in clear policy recommendations that can influence both EU and national policies.

By bringing together people with rare diseased and patient advocates, policy makers, healthcare industry representatives, clinicians, regulators and Member State representatives EURORDIS harnesses the power of this extensive network to shape goal-driven rare disease policies of the future.

Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.

Real World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs) to further reduce regulatory, payer, physician and patient uncertainty. Unfortunately, many companies struggle implementing it. The key ingredient to success is a cross-functional organisation where managers have widespread knowledge of the fundamentals and a shared vocabulary. In this course you will learn the fundamentals of RWE so that you can contribute effectively when decisions are made and/or when implementing RWE studies.

Join us in May 2026 for the third annual exclusive gathering of senior level investors, corporate executives, entrepreneurs and start-up leaders from biotech, tech bio, biomedical research, drug discovery and healthcare sectors.

Explore how real-world evidence can inform value, affordability, and access decisions for cell and gene therapies.

Policy makers and payers face mounting pressure to make evidence-based decisions that balance innovation with sustainable access. The healthcare ecosystem, real-world data, health economic models, and clinical outcomes assessments continuously demonstrate their ability to generate high-quality evidence and guide these decisions. Health economics and outcomes research (HEOR) stands at the forefront, providing rigorous data, frameworks, and insights needed to demonstrate value, guide resource allocation, and shape policies that matter.

Stay informed and connected by attending the US Pharma and Biotech Summit 2025. Organized by FT Live in collaboration with Endpoints News, the event will bring together top executives, investors and experts to share powerful insights into the future of life sciences in America and worldwide.

ACCESS Forum brings together Thought Leaders, Executives, and Key Stakeholders across Market and Patient Access several times a year to engage, get smarter, problem-solve and challenge the system.

Biosimilar medicines stand at the crossroads of access, sustainability, and industrial resilience. This year’s Biosimilar Medicines Conference programme will explore how strategic coalitions for change can emerge across value chains, geographies, and stakeholders to unlock the full potential of biosimilar medicines to deliver meaningful impact for patients, health systems and society at large.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.

This course examines the uses and limits of new methods for assessing health technologies in the early stages of research and development. Through real-world case studies and interactive learning, participants will learn how to frame the assessment, generate evidence, and produce insights relevant for decision-making, reflecting that information and implementation may be uncertain.

Europe's premier conference in the cell and gene therapy industry today.

Following a successful AXS26 Summit, Asembia is excited to be planning next year’s conference comprising networking sessions, exhibits and more. Each year, Asembia’s Specialty Pharmacy Summit is at the epicenter of the pharmacy industry, providing a unique opportunity for stakeholders throughout the industry to understand challenges, generate solutions and define the future.

The ABPI exists to make the UK the best place in the world to research, develop and access medicines and vaccines to improve patient care. We represent companies of all sizes which invest in making and discovering medicines and vaccines to enhance and save the lives of millions of people around the world.

The global collaborative network for leading pharma innovators

This course examines the uses and limits of new methods for assessing health technologies in the early stages of research and development. Through real-world case studies and interactive learning, participants will learn how to frame the assessment, generate evidence, and produce insights relevant for decision-making, reflecting that information and implementation may be uncertain.

This course offers a practical overview of market access and its application in business development and clinical strategy decisions. You’ll gain essential knowledge of payer expectations and HTA systems in Europe, and learn how access-related data should inform strategic decision-making. Through real-world examples and interactive group work, you’ll be equipped to make access-aware decisions in business development and clinical strategy